GHP Investment Advisors Inc. Buys 631 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

GHP Investment Advisors Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,232 shares of the biopharmaceutical company’s stock after purchasing an additional 631 shares during the period. GHP Investment Advisors Inc.’s holdings in Gilead Sciences were worth $942,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GILD. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC bought a new position in Gilead Sciences during the 3rd quarter valued at about $25,000. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at about $29,000. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock worth $3,033,340. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $89.00 on Monday. The stock has a market cap of $110.80 billion, a PE ratio of 108.54, a P/E/G ratio of 3.07 and a beta of 0.18. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The business’s 50-day simple moving average is $82.46 and its two-hundred day simple moving average is $73.48. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $89.74.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. As a group, analysts forecast that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.46%. Gilead Sciences’s payout ratio is 375.61%.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Truist Financial increased their target price on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Piper Sandler restated an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research note on Wednesday, September 11th. Finally, BMO Capital Markets increased their price objective on shares of Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.